• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

Demographic trends that boosted big gains in prior years haven't gone away.
By JOHN REESE
Jan 11, 2017 | 04:00 PM EST
Stocks quotes in this article: LMAT, SUPN, TARO, NVO, XLV

Health-care stocks are bouncing back after a brutal 2016, when they were the only major sector of the broader market to finish in negative territory.

Investors steered clear of drug makers on fears of a growth slowdown because of federal scrutiny over product pricing. There were also concerns about the looming fight over changes to the Affordable Care Act.

But the demographic trends that boosted big gains in prior years haven't gone away. An aging population bodes well for growth of drug makers as well as medical device manufacturers and managed care providers. It could be that last year's selloff has created some opportunities.

My firm Validea's health-care portfolio lagged last year, down 12.1% vs. a 9.5% gain in the S&P 500, but it has since rebounded strongly, rising 3.6% so far in 2017, almost triple the gain in the broad market. The portfolio is made up of the top-10 health-care stocks selected monthly by my consensus scoring system that utilizes the fundamental strategies of investment greats such as Warren Buffett, Peter Lynch, John Neff and a host of other stock selection models.

The Validea's Healthcare Portfolio has delivered a price return of 163% since Dec. 29, 2006 compared to a return of 56.8% for the S&P 500 and 149.6% for the Health Care Select Sector SPDR Fund (XLV) . The figures on Validea's portfolio don't include dividends, while the S&P and XLV are total return statistics inclusive of dividends.

Top holdings in the health-care portfolio currently include LeMaitre Vascular (LMAT) , Supernus Pharmaceuticals (SUPN) and Taro Pharmaceutical (TARO) .

A few things have come together to spark renewed interest in parts of the sector. The new administration in Washington comes in on the promise to rip up health insurance reforms, something that doesn't help the shares of hospital operators but does benefit biotech firms because the focus is seemingly off their big price hikes (although this was back in focus Wednesday after the president-elect's comments at his press conference).

The Danish insulin maker Novo Nordisk (NVO) is also on our list of top health-care stocks. Its shares fell 40% last year on concerns about pricing and competition, but the company has a dominant share of the market for diabetes care, with strong products and a solid pipeline. Sales tripled from 2005 to 2015.

This stock fits the model of famed investor Peter Lynch, who looked for hidden gems by examining a company's price-to-earnings ratio as it relates to growth. Novo Nordisk's P/E is 17.4 and its growth rate has been 21.6, making the stock look like an attractive buy.

Health-care stocks comprise the third largest chunk of the S&P 500 index at about 14%, making these stocks ripe for investors looking to sell other holdings and rotate back into a sector that has momentum -- as seen with the rotation into telecommunications and financial shares last year.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Reese and/or his private clients were long all stocks mentioned .

TAGS: Investing | U.S. Equity | Healthcare | ETFs | Funds | How-to | Stocks

More from Healthcare

Centene Shares Are Definitely Not Healthy

Bruce Kamich
Feb 6, 2023 9:58 AM EST

The healthcare enterprise reports earnings Tuesday before the market opens.

Look for More Upside in These 2 Stocks, Even Against a Challenging Backdrop

Bret Jensen
Feb 1, 2023 10:30 AM EST

Both names should see growth in 2023 and they're reasonably valued.

Does Intellia Therapeutics Stock Have Good Genes?

Bruce Kamich
Feb 1, 2023 8:49 AM EST

Let's check on the charts and indicators of the cutting-edge CRISPR editing company.

Let's Take a Look at Elevance Health Ahead of Earnings

Bruce Kamich
Jan 24, 2023 3:00 PM EST

What are chart patterns indicating?

Moderna Shares Surge on Promising Vaccine Results

Bruce Kamich
Jan 18, 2023 11:02 AM EST

Let's check the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:22 AM EST REAL MONEY

    LIVE EVENT: Bruce Kamich and Todd Campbell Share Their Stock Market Insights

    This Monday, Feb. 6 at 12 p.m., our very own exper...
  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • 11:35 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading an Irrational Market
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login